Cwm LLC Acquires 57 Shares of Becton, Dickinson and Company (NYSE:BDX)

Cwm LLC raised its position in Becton, Dickinson and Company (NYSE:BDX) by 0.6% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 8,965 shares of the medical instruments supplier’s stock after acquiring an additional 57 shares during the period. Cwm LLC’s holdings in Becton, Dickinson and Company were worth $2,161,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in BDX. Nordea Investment Management AB raised its stake in shares of Becton, Dickinson and Company by 277.3% in the first quarter. Nordea Investment Management AB now owns 1,936,654 shares of the medical instruments supplier’s stock valued at $478,295,000 after buying an additional 1,423,353 shares during the period. PineStone Asset Management Inc. grew its position in shares of Becton, Dickinson and Company by 141.6% in the second quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock valued at $314,544,000 after purchasing an additional 788,735 shares in the last quarter. M&G Plc purchased a new position in shares of Becton, Dickinson and Company in the first quarter valued at $173,692,000. First Eagle Investment Management LLC grew its position in shares of Becton, Dickinson and Company by 32.5% in the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock valued at $655,149,000 after purchasing an additional 688,296 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Becton, Dickinson and Company by 8.5% in the second quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock valued at $1,031,167,000 after purchasing an additional 346,720 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Price Performance

BDX opened at $240.02 on Tuesday. The stock has a 50-day moving average price of $236.46 and a 200-day moving average price of $235.25. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $262.23. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $69.37 billion, a P/E ratio of 52.87, a PEG ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. During the same period in the prior year, the business earned $2.96 EPS. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. Equities analysts predict that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were given a dividend of $0.95 per share. The ex-dividend date of this dividend was Monday, September 9th. This represents a $3.80 annualized dividend and a yield of 1.58%. Becton, Dickinson and Company’s payout ratio is 83.70%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Evercore ISI lifted their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Stifel Nicolaus boosted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Raymond James reduced their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Finally, Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.